Par Drugs & Chemicals Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Show Positive Recalibration

As of 20 Jul 2026, Par Drugs & Chemicals Ltd trades at a P/E ratio of 9.85, a level that remains modest compared to industry heavyweights and peer companies. This figure marks a slight increase from previous readings but still indicates a valuation that is attractive relative to the broader Chemicals & Petrochemicals sector, where many competitors command P/E multiples well above 15 or even 50. For instance, Stallion India and Sanstar Chemicals trade at P/E ratios of 56.85 and 62.49 respectively, underscoring Par Drugs’ relative affordability.

The company’s price-to-book value stands at 1.15, signalling that the stock is priced close to its net asset value. This is a critical metric for investors seeking value stocks, especially in the micro-cap segment where asset backing can provide a margin of safety. The EV to EBITDA ratio of 5.09 further supports the view that Par Drugs is trading at a reasonable enterprise valuation relative to its earnings before interest, taxes, depreciation and amortisation.

Comparative Peer Analysis Highlights Valuation Edge

When compared with peers, Par Drugs & Chemicals Ltd’s valuation metrics are markedly more attractive. Companies such as Titan Biotech and Indo Borax & Chemicals are classified as very expensive, with P/E ratios of 59.18 and 34.78 respectively, and EV to EBITDA multiples exceeding 28. Meanwhile, Gulshan Polyols, another attractive stock in the sector, trades at a higher P/E of 25.82 and EV to EBITDA of 11.46, nearly double that of Par Drugs.

This valuation gap suggests that Par Drugs offers a more compelling entry point for investors seeking exposure to the Chemicals & Petrochemicals sector without paying a premium. The company’s PEG ratio remains at 0.00, indicating either a lack of reported earnings growth estimates or a valuation that is not stretched relative to growth expectations.

Operational Efficiency and Returns Support Valuation

Beyond valuation multiples, Par Drugs & Chemicals Ltd demonstrates solid operational metrics. The latest return on capital employed (ROCE) stands at 19.15%, a robust figure that signals efficient use of capital to generate profits. Return on equity (ROE) is also respectable at 11.71%, reflecting decent profitability for shareholders. These returns underpin the company’s ability to sustain earnings and justify its current valuation.

Enterprise value to capital employed is low at 1.24, and EV to sales is 0.84, both indicating that the market values the company conservatively relative to its asset base and revenue generation. Such metrics are particularly important for micro-cap stocks, where volatility and risk are higher, and valuation discipline is crucial.

Price Performance Outpaces Benchmark Indices

Par Drugs & Chemicals Ltd has delivered strong short-term price returns, significantly outperforming the Sensex. Over the past week, the stock surged 17.14%, compared to a modest 0.53% gain in the Sensex. The one-month return of 10.62% also dwarfs the Sensex’s 1.03% rise. Year-to-date, Par Drugs has managed a positive 3.62% return while the Sensex declined by 6.87%, highlighting the stock’s resilience amid broader market weakness.

However, longer-term returns paint a more mixed picture. Over three years, the stock has declined by 46.84%, contrasting with a 23.45% gain in the Sensex. Similarly, the five-year return is negative 20.78%, while the benchmark index has appreciated by 52.82%. These figures suggest that while the stock has recently regained momentum, it has struggled to keep pace with the broader market over extended periods.

Price Range and Volatility

The stock’s current price of ₹104.93 is closer to its 52-week high of ₹122.43 than its low of ₹78.05, indicating a recovery phase. Today’s trading range between ₹95.60 and ₹111.70 reflects heightened volatility, consistent with the 10.42% day change. This volatility may attract traders seeking short-term gains but also warrants caution for risk-averse investors.

Micro-Cap Status and Market Capitalisation

Par Drugs & Chemicals Ltd remains classified as a micro-cap stock, which typically entails higher risk and lower liquidity compared to larger peers. The micro-cap grading aligns with its market capitalisation and trading volumes, factors that investors should consider when assessing portfolio allocation and risk tolerance.

Recent Rating Upgrade and Mojo Score

MarketsMOJO recently upgraded Par Drugs & Chemicals Ltd’s Mojo Grade from Sell to Hold on 16 Jul 2026, reflecting improved valuation and operational metrics. The current Mojo Score stands at 52.0, signalling a neutral stance that suggests neither a strong buy nor a sell recommendation. This upgrade indicates growing confidence in the company’s prospects, albeit with some caution due to its micro-cap nature and historical performance.

Investment Implications and Outlook

Par Drugs & Chemicals Ltd’s improved valuation parameters and recent price appreciation suggest a stock that is regaining investor interest. The attractive P/E and P/BV ratios relative to peers provide a compelling entry point for value-oriented investors. Additionally, solid returns on capital employed and equity support the company’s operational strength.

However, the stock’s longer-term underperformance relative to the Sensex and its micro-cap status imply elevated risk. Investors should weigh the potential for short-term gains against the volatility and liquidity constraints inherent in smaller companies. The recent Mojo Grade upgrade to Hold reflects this balanced view, recommending cautious optimism rather than aggressive accumulation.

Overall, Par Drugs & Chemicals Ltd appears to be a micro-cap stock with improving fundamentals and valuation appeal, but one that requires careful monitoring and selective exposure within a diversified portfolio.

Historical Valuation Context

Historically, Par Drugs & Chemicals Ltd’s valuation has oscillated between very attractive and attractive grades, with the current shift signalling a modest re-rating. The P/E ratio near 10 is consistent with a value stock profile, especially when contrasted with the sector’s more expensive names. This re-rating may reflect improved earnings visibility or market recognition of the company’s operational efficiencies.

Investors tracking valuation trends should note that the EV to EBIT ratio of 6.50 and EV to capital employed of 1.24 remain low, reinforcing the notion that the stock is not overvalued on an enterprise basis. These metrics provide additional layers of confidence for those seeking fundamentally sound investments in the Chemicals & Petrochemicals sector.

Conclusion

Par Drugs & Chemicals Ltd’s recent valuation upgrade and price performance highlight a stock that is becoming more attractive relative to its peers and historical levels. While the micro-cap status and past underperformance warrant caution, the company’s solid returns and reasonable multiples offer a compelling case for investors seeking value in the Chemicals & Petrochemicals space. The Hold rating and Mojo Score of 52.0 reflect a balanced outlook, suggesting that Par Drugs is worth monitoring closely as it navigates its growth trajectory and market dynamics.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →